Cipher Pharmaceuticals Inc. (CPH.TO)
| Previous Close | 14.95 |
| Open | 15.02 |
| Bid | 15.22 x 0 |
| Ask | 15.25 x 0 |
| Day's Range | 15.02 - 15.84 |
| 52 Week Range | 4.10 - 19.69 |
| Volume | |
| Avg. Volume | 75,496 |
| Market Cap | 391.761M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | 12.55 |
| EPS (TTM) | 1.22 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.64 |
The Motley FoolI’d Aim for $1 Million by Buying Just These 3 TSX Stocks
Investing in quality TSX stocks growing at a steady clip is a solid strategy to build long-term wealth and create a $1 million portfolio. The post I’d Aim for $1 Million by Buying Just These 3 TSX Stocks appeared first on The Motley Fool Canada.
ACCESSWIREKeynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in association with Small Cap Discoveries on September 25-26, 2024 at the Fairmont Waterfront Vancouver
VANCOUVER, BC / ACCESSWIRE / September 24, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VANCOUVER taking place on September 25-26, 2024, where 50 MicroCap public and private companies will be presenting at the Fairmont Waterfront ...
CNW GroupCipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its exp
